Subscribe To
ESAIY / Upside for Japanese pharma firm Eisai is still 'very, very strong,' says financial services firm
ESAIY News
By Yahoo Finance
October 28, 2023
Alzheimer's medication: Eisai reporting positive data on injectable drug
This segment originally aired on October 26, 2023. Eisai has (EISAY) reported positive results in clinical trials of their Alzheimer's drug- Leqembi. more_horizontal
By Market Watch
September 22, 2023
Merck and Eisai say two lung-cancer trials failed to meet their main goals
Merck and Japanese partner Eisai said Friday that two late-stage trials of a treatment for a certain type of non-small lung cancer failed to meet thei more_horizontal
By InvestorPlace
September 4, 2023
The 3 Best Biotech Stocks to Buy Now: September 2023
Biotech stocks have underperformed in the U.S. stock market by a wide margin this year. The sector's most popular index, the iShares Biotechnology ETF more_horizontal
By Proactive Investors
August 25, 2023
Merck and Eisai cull late-stage study for head and neck cancer therapy
Merck & Co Inc (NYSE:MRK) and research partner Eisai said they are halting a late-stage trial that used a combination of drugs to treat a type of head more_horizontal
By Market Watch
August 25, 2023
Merck and Eisai say late-stage trial of treatment for head and neck cancer did not meet goals
Merck & Co. Inc. MRK, -1.66% and Eisai Co. Ltd. 4523, -1.23% ESAIY, -1.95% said Friday a late-stage trial of a treatment for head and neck cancer fail more_horizontal
By Reuters
August 25, 2023
Merck, Eisai discontinue late-stage study for cancer therapy
Merck & Co and partner Eisai said on Friday they will shut down a late-stage study testing an experimental combination therapy for a type of head and more_horizontal
By InvestorPlace
July 30, 2023
3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes
The pharmaceutical sector generates a huge $1.2 trillion of revenue globally, and the U.S. is by far the most lucrative country for drug makers in the more_horizontal
By PRNewsWire
July 11, 2023
EISAI TO PRESENT THE LATEST ALZHEIMER'S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023
TOKYO , July 11, 2023 /PRNewswire/ -- Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the more_horizontal